All of Ranbaxy's India-based factories are currently banned by the FDA from exporting medicines to the United States, the company's largest market, after the regulator's inspection found violation of its so-called good manufacturing practices.
The drug Glivec was a genuinely new and important discovery deserving of patent protection.
Companies known for spending huge amounts on innovation globally have minuscule budgets for India. What's holding them back?
Increased price control over branded generic medicines has affected its profitability
A random check had found that tests failed to prove the medicines were same as the patented drugs.\n
Industry must take strong collective action to protect the reputation it enjoys in global markets, says Kiran Mazumdar Shaw.
Firm pleads guilty to lying to US FDA; says it had set aside the money.
The move assumes significance because a go-ahead from the US Food and Drug Administration for the new unit in Visakhapatnam is likely to give a huge boost to the company's revenues in upcoming quarters.
Indian companies may be able to make generic copies of Roche's anti-influenza drug Tamiflu with its patent still pending in the country.
Dhoom 3 boasts of more noise, more bikes and a whole lot of scowling from Aamir Khan.
Court has barred generic drugmaker Cipla Ltd from making or selling a cheaper copy of Novartis AG's respiratory drug Onbrez domestically.
Novartis' threat that it would not introduce new medicines in India after the verdict is hollow, says Anand Grover.
The company had stopped production of generic version of cholesterol lowering drug Lipitor last year as it investigated the issue of potential glass particles in certain lots of the drug.
In a landmark judgment that has the potential to change the direction of India's pharmaceutical business, the apex court said on Monday that the drug failed to qualify for a patent according to Indian law.
If it gets the USFDA nod, the sales would help to pull the company out of the red.
The difference between watching a movie on a laptop in your apartment and watching it on a big white screen is almost spiritual, notes Sreehari Nair.
Companies run till now by mostly their promoters are increasingly inducting professionals to head their teams.
An insider said that over the past decade or so Cipla has become immune to the exits of leaders. There have been no directional change in the long-term strategies.
Take the rediff business quiz and see how much you know about India's pharmaceutical industry.
Expectations of Healthcare sector from Union Budget 2013-14.
Observing that the economic recovery was not yet fully entrenched, the RBI Governor said recovery is likely to be gradual.
Prodded by patent cliff & increasing competition, it files application for foray into injectible oncology segment.
In a landmark judgment that has the potential to change the direction of India's pharmaceutical business, the Supreme Court said on Monday that the drug failed to qualify for a patent according to Indian law.
'In states where all shops are allowed to function and pedestrians are allowed to move around, there is no reason to presume that vendors are not allowed to operate. But ambiguity surrounding the operation of street vendors de jure has led the police to harass them de facto,' say Bhuvana Anand, Jayana Bedi and Prashant Narang.
The Pradhan Mantri Jan Aushadhi Yojana or PMJAY has not been a runaway success by any yardstick. Not all stores are running, and many are poorly stocked.
India's Orchid Chemicals & Pharmaceuticals Ltd said on Monday that US-based Apotex Corporation would sell its generic cephalosporins and other injectible antibiotics in the United States.\n\n\n\n
Bayer will not accept a ruling by the Intellectual Property Appellate Board in Chennai on Monday, upholding the compulsory licence granted on March 9 last year and it will appeal against the patent office order at the high court in Mumbai, a spokesperson told PTI.
GVK Biosciences is the latest Indian firm to come under international scrutiny over quality issues.
Ahmedabad-based Zydus Cadila has made a foray into the US generic formulation segment by setting up a subsidiary Zydus Pharmaceuticals USA, Inc.
In a bid to tap overseas market, Glenmark Pharmaceuticals Ltd's wholly owned US subsidiary has entered into a product development and marketing licence agreement with US-based K V Pharmaceutical Company
An interview with Ranbaxy CEO and MD Arun Sawhney on the changes in the past four years and how the company plans to address the US concerns.
For far too long, people in J&K have felt the government doesn't exist for them.' 'My first priority is to make them feel that not only does it exist, it is there to work for them.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances